Benzene Ring Bonded Directly To The Hetero Ring (e.g., Flavones, Etc.) Patents (Class 549/403)
  • Patent number: 10196522
    Abstract: A method of separating oil-soluble pigment and water-soluble pigment from natural material using aerogels characterized in comprising the steps of: (A) immersing a natural material in a leaching solvent to extract a pigment; (B) mixing the leaching solution from which pigment is extracted in step (A) with aerogel to adsorb oil-soluble pigment to aerogels; (C) separating oil-soluble pigment adsorbed on the surface of aerogel in step (B); (D) drying and concentrating the pigment separated in step (C), enhancing a method of separating from natural material the initial substance for pharmaceuticals, food, cosmetics, etc. facilitating a safer and more efficient production process compared to the conventional separation method.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: February 5, 2019
    Assignee: ARCA EIR INC.
    Inventors: Byong Cheol Shin, Bo Ram Han, Su Jin Lim, Hark Mo Seong
  • Patent number: 10172824
    Abstract: The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 8, 2019
    Assignees: YUNNAN INSTITUTE OF MATERIA MEDICA, HLK PHARMACEUTICALS CO., LTD.
    Inventors: Zeren Wang, Jun Xu, Minghui Wang, Zhaoyun Zhu, Jingkun Wang, Shuangxi Mei, Wenqiang Sun, Tao Cui
  • Patent number: 9822090
    Abstract: The invention relates to a process for producing Nebivolol hydrochloride, (formula I) comprising the steps of: provision of a protected Nebivolol hydrochloride of the general formula (II), with P being an amine protecting group, and hydrogenation of said protected Nebivolol hydrochloride yielding Nebivolol hydrochloride of the formula (I).
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 21, 2017
    Assignee: CORDEN PHARMA INTERNATIONAL GMBH
    Inventors: Alexandre Clavel, Ilia Freifeld, Gerhard Jas, Kurt Kesseler
  • Patent number: 9556140
    Abstract: A process for synthesis of enatiomerically pure or enatiomerically enriched or racemic mixture of (+ and/or ?) epicatechin and its intermediates, comprising the steps of: (i) obtaining penta-protected quercetin; (ii) reducing the penta-protected quercetin obtained from step (i); (iii) optionally deprotecting the compound of step (ii); (iv) reducing the compound obtained from step (ii) or step (iii) in the presence of a chiral/achiral reducing agent to obtain a chiral intermediate; (v) deprotecting and/or hydrogenation of the chiral intermediate obtained from step (iv) to obtain (?)-epicatechin; (vi) optionally simultaneously deprotecting and by drogenation of the compound obtained from step (ii) to obtain racemic epicatechin.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: January 31, 2017
    Assignee: Sphaera Pharma Pvt. Ltd.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Kumar Santosh Rai, Vinayak Tripathi, Ishwar Rakesh Patil
  • Patent number: 9457007
    Abstract: The present invention is directed to a novel use of prenylflavanone compounds for control of blood glucose and treatment or prevention of diabetes.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 4, 2016
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: Chia-Nan Chen, Li-Ling Chi
  • Patent number: 9381186
    Abstract: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: July 5, 2016
    Assignee: MEI PHARMA, INC.
    Inventors: Andrew Heaton, Alan James Husband
  • Patent number: 9296717
    Abstract: The preparation of C-3 coupled biflavonoids and C-3 coupled biflavonoid analogs occurs from flavan-3-ones that are contacted with a compound having a nucleophilic aromatic moiety, in the presence of a Lewis acid where an intermediate compound is formed with a C-3 hydroxy group. A flavan-3-ol can be converted to a flavan-3-one as required. The intermediate compound is dehydrated to a flavene with a C-3-C-4 double bond. The flavene compound undergoes hydroboration-oxidation hydration to introduce a C-4 hydroxy group that can be oxidized to an oxo group or can be dihydroxylation to introduce hydroxy groups at the C-4 and C-3 carbons and dehydrated to a biflavonoid or biflavonoid analog having an oxo group at its C-4 carbon and substituted by the selected nucleophilic aromatic moiety on its C-3 carbon.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: March 29, 2016
    Assignee: UNIVERSITY OF THE FREE STATE
    Inventors: Jan Hendrik Van Der Westhuizen, Susanna Lucia Bonnet, Mathew Achilonu, Miroslav Sisa
  • Patent number: 9187447
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: November 17, 2015
    Assignee: Nivalis Therapeutics, Inc.
    Inventors: Xicheng Sun, Jian Qiu
  • Patent number: 9090583
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 28, 2015
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li
  • Publication number: 20150148551
    Abstract: The subject of the invention is genistein for use in non-enzymatic method of treatment and/or prevention of the lysosomal storage diseases (LSDs) i.e. diseases with the underlying defect in degradation and resulting accumulation of organic compounds in lysosomes, to reduce the level of storage of organic compounds by reducing the rate of efficiency of accumulating organic substances synthesis and/or by increasing the rate of efficiency of cellular deposits degradation.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 28, 2015
    Inventors: Grzegorz Wegrzyn, Magdalena Angelina Gabik-Ciminska, Joanna Jakobkiewicz-Banecka, Marta Moskot
  • Publication number: 20150148409
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 28, 2015
    Inventors: Guangdi WANG, Matthew E. BUROW, Stephen M. BOUE, Thomas E. WIESE, Quan JIANG
  • Patent number: 9029561
    Abstract: Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-dihydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: May 12, 2015
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Patent number: 9012495
    Abstract: The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: April 21, 2015
    Assignee: Axcentua Pharmaceuticals AB
    Inventors: Anders Berkenstam, Stefan Rehnmark, Michael-Robin Witt, Keith Lorimer, Stephen Watt
  • Publication number: 20150087699
    Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    Type: Application
    Filed: May 3, 2013
    Publication date: March 26, 2015
    Inventors: Jayaraman V. Raman, Swaroop K. Vakkalanka
  • Publication number: 20150065698
    Abstract: There is described a method of isolating one or more of pectin, d-limonene, a flavour compound, a flavonoid, a soluble monosaccharide, a decomposition product of a monosaccharide and cellulose, from citrus material wherein said method comprises the microwave assisted hydrothermal low temperature treatment of citrus material.
    Type: Application
    Filed: April 4, 2013
    Publication date: March 5, 2015
    Inventors: James Hanley Clark, Lucie Anne Pfaltzgraff, Vitaliy Lvovich Budarin, Mario De Bruyn
  • Patent number: 8969596
    Abstract: Subject of the invention is a method for the production of isoflavanes from isoflavones, whereby in a first reaction step (a) the 4-keto group of the isoflavone is reduced in a enantioselective manner, whilst the 2,3-double bond is maintained, to the 4-hydroxy compound.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: March 3, 2015
    Inventor: Bert Steffan
  • Publication number: 20150056166
    Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
  • Patent number: 8962679
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 24, 2015
    Assignees: The Administrators of the Tulane Educational Fund, Xavier University of Louisiana
    Inventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
  • Publication number: 20150050410
    Abstract: The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 19, 2015
    Applicant: CHROMOCELL CORPORATION
    Inventors: Robert Zhiyong Luo, Kevin Joseph Curran, Stuart Hayden, Gengcheng Yang
  • Publication number: 20150051270
    Abstract: A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as here in below defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituen
    Type: Application
    Filed: February 15, 2013
    Publication date: February 19, 2015
    Inventors: Shailesh Mistry, Etíenne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
  • Publication number: 20150045423
    Abstract: The present invention relates to new compounds which are inter alia derivable from hops for use in the treatment of (for treating)/prevention or healing of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage (and/or for the prevention of aggrecan loss). Food products comprising these compounds for use in the treatment (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage, are also envisaged.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 12, 2015
    Inventors: Peter Prehm, Dennis Stracke
  • Publication number: 20150045358
    Abstract: A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins.
    Type: Application
    Filed: May 21, 2013
    Publication date: February 12, 2015
    Inventors: Yung-hsi KAO, Ya-chu Tang, Hsin-huei Chang, Hui-chen Ku
  • Publication number: 20150038571
    Abstract: The present invention relates to a composition having antiviral activity for prophylaxis or treatment of flavivirus infection or a disease resulting therefrom in humans or animals, characterised in that said composition consisting of baicalein, or analogues, or derivatives thereof. The composition may further comprise a pharmaceutically acceptable carrier. The antiviral activity may include inhibition of virus attachment to host cells, inhibition of intracellular virus replication and direct virucidal activity. The flavivirus may comprise dengue virus type-1, dengue virus type-2, dengue virus type-3, dengue virus type-4 and Japanese encephalitis virus.
    Type: Application
    Filed: January 16, 2013
    Publication date: February 5, 2015
    Inventor: Sazaly Abu Bakar
  • Patent number: 8946287
    Abstract: Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: February 3, 2015
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, John M. Pezzuto, Arup Mati
  • Patent number: 8946457
    Abstract: Flavone derivatives, preparative method of the derivatives and use thereof as medicaments for treating diabetes. The structure of the derivatives is presented by formula 1: In the structure, R1 and R2, which are identical or not, represent hydrogen atom, halogen, cyano, hydroxyl, trifluoromethyl, thio-methyl, benzyloxy. C1-C8 linear chain or branch chain alkyl, C1-C8 linear chain or branch chain alkoxy. The pharmacological test indicates that the flavone derivatives can significantly increase the glucose consumption of Hep-G2 cell with insulin resistance activity, promote translocation of glucose transporter 4 of skeletal muscle cells (L6GLUT4myc) at different level, and significantly increase glucose intake and utilization by cells.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: February 3, 2015
    Assignee: Tianjin Medical University
    Inventors: Hongquan Duan, Nan Qin, Wenyan Niu, Meina Jin, Lihuan Shi, Ying Chen
  • Patent number: 8946288
    Abstract: The invention discloses the uses of hydroxyl polymethoxylflavones and derivative thereof that are relative to inhibit adipogenesis and lower lipid accumulation, wherein the hydroxyl polymethoxylflavones is obtained from the peels of Citrus genus plants. Therefore, the hydroxyl polymethoxylflavones that of a therapeutically effective amount not only can be a medical compound for treatment obesity or fatty liver, but also can be a food element.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: February 3, 2015
    Assignees: Greenyn Biotechnology Co., Ltd.
    Inventors: Min-Hsiung Pan, Chia-Li Wu
  • Patent number: 8940789
    Abstract: A method for producing 4?-demethylnobiletin or 4?-demethyltangeretin including fermenting a skin derived from at least one citrus fruit selected from citrus fruits belonging to section Acrumen in subgenus Metacitrus in genus Citrus or citrus fruits belonging to section Aurantium in subgenus Archicitrus in genus Citrus, or a water extract product thereof using one or more Aspergillus molds selected from Aspergillus kawachii, Aspergillus awamori, Aspergillus oryzae, Aspergillus sojae, Aspergillus saitoi, and Aspergillus usamii to obtain a fermented product.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: January 27, 2015
    Assignee: Fuji Sangyo Co., Ltd.
    Inventors: Shuichi Kusano, Hiroshi Tamura
  • Patent number: 8933252
    Abstract: Provided are: a method for rapid fluoromethylation, by which a fluoromethyl group can be easily bonded to an aromatic-ring carbon of an aromatic compound with little generation of by-products; and a process for preparation of a PET tracer using the same. The method is characterized by cross-coupling an organoboron compound in which an aromatic ring is bonded to a boron atom with FCX2Br (wherein X is ordinary hydrogen or heavy hydrogen) in a solvent obtained by adding water to an aprotic polar solvent, in the presence of a palladium complex, a phosphine ligand, and a base.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: January 13, 2015
    Assignee: Riken
    Inventors: Masaaki Suzuki, Hisashi Doi, Miki Goto
  • Publication number: 20140356462
    Abstract: An extract of Citrus depressa, preferably an organic solvent extract of a fruit and/or leaf of Citrus depressa, a supercritical extract of a fruit and/or leaf of Citrus depressa, or a subcritical extract of a fruit and/or leaf of Citrus depressa, containing 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter, for example, 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid, such as nobiletin and tangeretin, is used as an active ingredient of a muscle atrophy inhibitor.
    Type: Application
    Filed: December 26, 2012
    Publication date: December 4, 2014
    Inventors: Yasuyuki Sakata, Hirohiko Nakamura, Kazutaka Oshio
  • Publication number: 20140348966
    Abstract: Embodiments of the present disclosure related to compounds and compositions derived from G. buchananii baker and methods thereof.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 27, 2014
    Inventors: Onesmo B. Balemba, Thomas Hofmann, Sofie Pasilis, Gary M. Mawe, Stuart M. Brierley, Gemma Mazzuoli, Timo Stark, Michael Schemann, Dagmar Kruger
  • Publication number: 20140348961
    Abstract: The present invention provides a sirtuin activator with an active component composed of black ginger or a black ginger extract, which is easily obtainable, extremely safe, and eaten from old. The present invention further provides a sirtuin activator with an active component of polyalkoxyflavonoid compound represented by general formula (I) and having a sirtuin activation effect that is 10 folds that of resveratrol or higher: wherein, R1 to R7 are each independently a hydrogen atom, a hydroxyl group, or a C1 to C6 lower alkoxy group.
    Type: Application
    Filed: December 27, 2012
    Publication date: November 27, 2014
    Applicants: TOKIWA PHYTOCHEMICAL CO., LTD.
    Inventors: Tsutomu Shimada, Jinwei Yang, Yuka Koike
  • Publication number: 20140336247
    Abstract: Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating cardiovascular diseases.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 13, 2014
    Inventors: Jun Bai, Caiyue She, Shigao Hu
  • Publication number: 20140329279
    Abstract: Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 6, 2014
    Inventors: Min Wang, Patrick M. Hossler, Sean W. McDermott, Christopher Racicot, Kofi Chemfe, John Fann
  • Publication number: 20140296543
    Abstract: The present invention is directed to a novel use of prenylflavanone compounds for control of blood glucose and treatment or prevention of diabetes.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: CHIA-NAN CHEN, LI-LING CHI
  • Patent number: 8846752
    Abstract: Isoflavone fatty acid ester derivatives of formula (I) or (II), the preparation method thereof and the pharmaceutical compositions containing such compounds are disclosed. The uses of such compounds in preparation of medicaments for preventing or treating hyperlipidemia, obesity or type II diabetes are also disclosed.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: September 30, 2014
    Assignees: China Pharmaceutical University, Nanjing Medical University Affiliated Brain Hospital
    Inventors: Hua Xiang, Wei Zhao, Hong Xiao, Yao Yao, Renling Ma, Lei Qian, Xiaobo Li, Qidong You, Qingjiang Liao
  • Publication number: 20140288168
    Abstract: The present invention provides a medicinal and/or a food usage of eupatilin for treating, improving, and/or preventing at least one condition selected from bone disease, menopausal disorder, cardiovascular disease, neurodegenerative disease, or obesity. Advantages of the present invention includes little or no possibility of side effects such as cancer, and effective treatment, improvement, and/or prevention of the at least one condition selected from bone disease, menopausal disorder, cardiovascular disease, neurodegenerative disease, and obesity.
    Type: Application
    Filed: September 27, 2012
    Publication date: September 25, 2014
    Inventors: Jung-Hye Choi, Kyung-Tae Lee, Ji-Hyun Kim, Nam-In Baek
  • Publication number: 20140275185
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: N30 PHARMACEUTICALS, INC.
    Inventors: Xicheng Sun, Jian Qiu
  • Patent number: 8835490
    Abstract: The invention provides methods for one or more of enhancing energy metabolism, promoting healthy energy metabolism, maintaining healthy energy metabolism, preventing conditions that result in a decline or deficiency in energy metabolism, treating conditions that result in a decline or deficiency in energy metabolism, and preventing the accumulation of excess body fat in animals without reducing energy intake by the animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 16, 2014
    Assignee: Nestec SA
    Inventor: Yuanlong Pan
  • Patent number: 8802147
    Abstract: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: August 12, 2014
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Publication number: 20140221468
    Abstract: Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired.
    Type: Application
    Filed: December 9, 2011
    Publication date: August 7, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chan Young Park, Amir M. Sadaghiani, Ricardo Ei Dolmetsch
  • Publication number: 20140221319
    Abstract: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 7, 2014
    Applicants: Mayo Foundation for Medical Education and Research, President and Fellows of Harvard College
    Inventors: David A. Sinclair, Nathan L. Price, Eduardo N. Chini, Jon C. Clardy, Shugeng Cao
  • Patent number: 8778986
    Abstract: The bioflavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: July 15, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
  • Publication number: 20140186328
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 3, 2014
    Applicant: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • Publication number: 20140186277
    Abstract: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced skin damage, and related compositions, e.g., cosmetic compositions.
    Type: Application
    Filed: September 5, 2013
    Publication date: July 3, 2014
    Applicants: Shiseido Co., Ltd., The General Hospital Corporation
    Inventors: Sam W. Lee, Lakshmi Raj, Anna I. Mandinova, Haruhi Iwaki, Yuji Katsuta, Jotaro Nakanishi
  • Patent number: 8759548
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 24, 2014
    Assignee: N30 Pharmaceuticals, Inc.
    Inventors: Xicheng Sun, Jian Qiu
  • Patent number: 8742141
    Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: June 3, 2014
    Assignee: Northwestern University
    Inventors: Raymond C. Bergan, Karl A. Scheidt
  • Publication number: 20140148504
    Abstract: The present invention relates to a novel use of a flavone-based compound or a Kaempferia parviflora extract comprising the same. More particularly, the present invention relates to a composition for wrinkle improvement, anti-aging and skin elasticity enhancement or a composition for skin moisturization, which comprises a flavone-based compound or a Kaempferia parviflora extract comprising the same as an active ingredient. The composition of the present invention is very effective in inhibiting the activity of Collagenase-1 (MMP-1) and promoting the synthesis of collagen. Therefore, the composition of the present invention is useful for wrinkle improvement, anti-aging, skin elasticity enhancement, and skin moisturization via the inhibition of moisture loss from the skin.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 29, 2014
    Applicant: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Jae Kwan Hwang, Jaekyung Kim
  • Publication number: 20140141510
    Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
    Type: Application
    Filed: April 10, 2012
    Publication date: May 22, 2014
    Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Lars Zender, Torsten Wuestefeld
  • Patent number: 8716497
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 6, 2014
    Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Patent number: 8710097
    Abstract: Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers are developed in this invention, which are linked together by linker groups of various lengths. These flavonoid dimers are found to be efficient P-gp modulators that increase cytotoxicity of anticancer drugs in vitro and dramatically enhance their intracellular drug accumulation. It is found that the flavonoid dimers of this invention is also useful in reducing drug resistance in treating parasitic diseases.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: April 29, 2014
    Assignees: The Hong Kong Polytechnic University, McGill University
    Inventors: Tak-Hang Chan, Larry Ming-Cheung Chow